Compare Davita Inc (DVA) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Infosys Limited — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Infosys Limited trades at $10.71 (market cap $41.74B). The key difference: Infosys Limited is far larger — about 3.7× Davita Inc's market cap, and Infosys Limited pays a 4.89% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Infosys Limited for 27 Days on average.
| DVA | INFY | |
|---|---|---|
Market Cap | $11.29B | $41.74B |
Volume | 582,204 | 31,354,285 |
Sector | Health | Technology |
52-Week High | $240.96 | $20.22 |
52-Week Low | $103.87 | $10.49 |
Typical Hold Time | 113 Days | 27 Days |
Enterprise Value | $24.01B | $39.48B |
Dividend Yield | — | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Infosys (INFY) trades at $10.55, showing no change in the latest session. The stock is in a bearish technical trend with key support at $10 and resistance at $11. Fundamentally, the company reported strong profitability with a net income margin of 16.37% and ROE of 32.12% for 2025. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro, to drive innovation. However, cash flow trends show a projected decline in net cash flow for 2026.
The outlook for INFY is mixed. Positive fundamentals and strategic partnerships offer growth potential, but bearish technicals and a projected cash flow decline pose risks. Analyst consensus is a 'Hold' with a price target of $11.48, suggesting limited near-term upside. Investors should weigh strong profitability against execution risks in a competitive IT services market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
